secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001104659-24-040521
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech 2023 rev $84.5M; net loss $(68.7)M; DFD-29 PDUFA Nov 4, 2024
-----------------------------------------------------------------------------

- Record consolidated net revenue $84.5M in 2023, up from $75.7M in 2022; net loss $(68.7)M ($8.47/share) vs $(94.6)M ($15.97).
- Cash $83.4M at Dec 31, 2023, down $97.6M YoY; raised ~$34.9M in 2023/early 2024 offerings.
- FDA accepted DFD-29 NDA for rosacea; PDUFA date Nov 4, 2024; up to 4 NDA/BLA decisions in next 18 months.
- Cosibelimab BLA received CRL in Dec 2023 (manufacturing only); resubmission expected for 2024 approval.
- Journey Medical product net revenues fell to $59.7M from $71.0M; total net rev $79.2M (+7%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465924040521/0001104659-24-040521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465924040521/tm2410123d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-040521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer